Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jim Glasheen
AddedMar 31, 2024
UpdatedMay 31, 2026
Jim Glasheen

Jim Glasheen

Co-Founder, Clade Therapeutics

CrunchbaseLinkedIn

Jim Glasheen's Career

Clade Therapeutics
Clade Therapeutics

Boston, MA, US

Co-Founder
Elcelyx Therapeutics
Elcelyx Therapeutics

San Diego, CA, US

Board Member· Board
Atalanta Therapeutics
Atalanta Therapeutics

Boston, MA, US

Co-Founder
Tria Beauty
Tria Beauty

Dublin, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jim Glasheen's Career

Clade Therapeutics
Clade Therapeutics
Acquired$87M02020Boston, MA, US
Co-Founder

Leadership at Clade Therapeutics

Leandro VetcherLeandro VetcherCo-Founder
Chad CowanChad CowanCo-Founder

Similar to Clade Therapeutics

Claradele PharmaceuticalsClaradele PharmaceuticalsGreenville, NC, USCancer Therapeuticsest. 2020Claradele PharmaceuticalsGreenville, NC, US · est. 2020

Claradele Pharmaceuticals: A biotech firm innovating non-toxic, effective cancer treatments.

Angel · $75k50
Celsius TherapeuticsCelsius TherapeuticsCambridge, MA, USTherapeuticsest. 2018Celsius TherapeuticsCambridge, MA, US · est. 2018

Celsius Therapeutics, a US-based biotech firm, develops drugs for cancer and autoimmune diseases.

Series B · $148M72
Garuda TherapeuticsGaruda TherapeuticsCambridge, MA, USStem Cell Therapiesest. 2021Garuda TherapeuticsCambridge, MA, US · est. 2021

Garuda Therapeutics: Developing ready-to-use stem cell therapies for severe diseases.

Series B · $134M67
Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
Elcelyx Therapeutics
Elcelyx Therapeutics
Series E$96.8M92010San Diego, CA, US
Board Member· Board

Leadership at Elcelyx Therapeutics

Brook ByersBrook ByersBoard Member
Ginger GrahamGinger GrahamBoard Member
Bosun HauBosun HauBoard Member
Alain BaronAlain BaronBoard Member
Atalanta Therapeutics
Atalanta Therapeutics
Series A$110M622018Boston, MA, US
Co-Founder

Leadership at Atalanta Therapeutics

Anastasia KhvorovaAnastasia KhvorovaCo-Founder
Craig MelloCraig MelloCo-Founder
Neil AroninNeil AroninCo-Founder
Alicia SecorAlicia SecorCEO
Tria Beauty
Tria Beauty
Acquired$288M02003Dublin, CA, US
Board Member· Board

Leadership at Tria Beauty

Peter WylesPeter WylesCEO
David MauneyDavid MauneyBoard Member
Albert ChaAlbert ChaBoard Member
Tobin IslandTobin IslandFounder
Dayton MisfeldtDayton MisfeldtBoard Member
Michael ValentinoMichael ValentinoBoard Member

Similar to Tria Beauty

FutureDermFutureDermPittsburgh, PA, USProducts, Skincareest. 2012FutureDermPittsburgh, PA, US · est. 2012

FutureDerm: Your global online hub for science-backed skincare insights and products.

Angel · $682.8k5
CureSkinCureSkinBangalore, Karnataka, INSkincare, Treatment Kitsest. 2016CureSkinBangalore, Karnataka, IN · est. 2016

AI-powered skin-care solutions delivered to your doorstep. Get personalized treatment plans from CureSkin.

Series A · $5.5M30
StratiaStratiaBoston, MA, USCosmetics, Skincareest. 2016StratiaBoston, MA, US · est. 2016

Stratia: Your online destination for premium skincare products.

Seed · $2M8
Function of BeautyFunction of BeautyNew York City, NY, USHair Care, Skin Careest. 2015Function of BeautyNew York City, NY, US · est. 2015

Custom beauty brand crafting personalized hair, skin, and body care through tech and innovation.

Late Stage Private · $247.9M200

Jim Glasheen's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Jim Glasheen

Jonathan LiptonJonathan LiptonCo-Founder · CladeZach MalchanoZach MalchanoCo-Founder · InSite Medical TechnologiesJason RudinJason RudinFounder & CEO · CladSukumar NagendranSukumar NagendranBoard Member · Taysha Gene TherapiesLaura Hix GlickmanLaura Hix GlickmanCo-Founder · Actym Therapeutics